Yang, Xiaochen
Lam, Wing
Jiang, Zaoli
Guan, Fulan
Han, Xue
Hu, Rong
Cai, Wei
Cheng, William
Liu, Shwu-Huey
Cheng, Peikwen
Cai, Yuping
Rattray, Nicholas J. W.
Johnson, Caroline H.
Chen, Lieping
Cheng, Yung-Chi
Funding for this research was provided by:
National Cancer Institute (PO1CA154295-01A1, PO1CA154295-01A1, PO1CA154295-01A1, PO1CA154295-01A1)
Article History
Received: 1 March 2021
Accepted: 24 May 2021
First Online: 29 June 2021
Competing interests
: Yung-Chi Cheng is the inventor of the use of YIV-906 with Anti-PD1 and Anti-PDL1 for treatment of cancer. The patent is owned by Yale University. Yale University had licensed this patent to Yiviva. S.H Liu, William Cheng and Peikwen Cheng are employed by Yivvia. Wing Lam and Fulan Guan are consultant for Yiviva Inc. The rest of authors had no conflicts interests.